Skip to main content
ORTHOCELL LIMITED logo

ORTHOCELL LIMITED — Investor Relations & Filings

Ticker · OCC ISIN · AU000000OCC6 ASX Manufacturing
Open in API
Filings indexed 780 across all filing types
Latest filing 2024-02-21 Capital/Financing Update
Country AU Australia
Listing ASX OCC

About ORTHOCELL LIMITED

https://orthocell.com/

Orthocell Limited is a regenerative medicine company focused on the development and commercialization of innovative technologies for the repair and regeneration of human soft tissue. The company’s core product portfolio includes the CelGro platform, a naturally derived collagen medical device designed to facilitate tissue repair and reconstruction in applications such as dental bone and soft tissue regeneration, nerve repair, and tendon repair. Orthocell also specializes in advanced cellular therapies, notably Ortho-ATI (Autologous Tenocyte Implantation) for treating chronic tendon injuries and Ortho-ACI (Autologous Chondrocyte Implantation) for cartilage repair. These therapies utilize a patient's own cells to restore function and structure to damaged tissues. The company aims to provide restorative solutions that improve clinical outcomes and offer alternatives to traditional surgical interventions.

Recent filings

Filing Released Lang Actions
Proposed issue of securities - OCC 5 pages 17.7KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B - Proposed issue of securities' and details a placement or other type of securities issue by Orthocell Limited. It includes specifics such as the number of securities to be issued, issue price, proposed issue date, and conditions related to the placement. The content is consistent with a formal announcement of a capital raising or securities issuance event. There is no financial performance data, management discussion, or audit information. The document is not a report but an announcement of a capital/financing update. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (6266 characters) supports it being a full announcement rather than a brief notice or report publication announcement.
2024-02-21 English
Trading Halt 3 pages 584.5KB
Capital/Financing Update Classification · 95% confidence The document is a market announcement from Orthocell Limited regarding a trading halt requested pending an announcement related to a proposed strategic placement (capital raising). It is a short notice informing the market about the trading halt and the reason for it, without containing any financial data or detailed report. The document does not contain an actual capital raising report or financial statements but is an announcement about an upcoming event related to capital/financing. Therefore, it fits best under Capital/Financing Update (CAP). The document length is 5077 characters, which is short and consistent with an announcement rather than a full report.
2024-02-19 English
Remplir Expansion Continues with Singapore Application 2 pages 230.1KB
Capital/Financing Update Classification · 90% confidence The document is a press release announcing the submission of a regulatory application for a medical product (Remplir) to the Health Services Authority of Singapore. It discusses the company's regulatory strategy, market expansion, and product adoption but does not contain financial statements, detailed financial performance data, or comprehensive report content. The document is relatively short (6023 characters) and serves as an update on regulatory and market progress rather than a formal financial or management report. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a certification or officer attestation. It is also not a regulatory filing in the sense of compliance documents or insider transactions. The content is best classified as a Capital/Financing Update (CAP) because it relates to regulatory approval progress, which is a key step in the company's capital and market expansion strategy, impacting future financing and market positioning. Therefore, the most appropriate classification is CAP with high confidence.
2024-02-12 English
Notification of cessation of securities - OCC 5 pages 16.3KB
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Appendix 3H - Notification of cessation of securities' and details the cessation of certain securities (options) for Orthocell Limited, including the number of securities ceased, reasons for cessation, and updated issued capital figures. It is a regulatory announcement related to changes in the company's issued capital due to expiry of options. There is no financial report, earnings data, or management discussion. The document is a formal notification to the ASX about securities cessation, fitting the category of Share Issue/Capital Change announcements rather than a full report or other categories.
2024-02-05 English
Quarterly Activity Report & Appendix 4C 10 pages 593.6KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Quarterly Report – December 2023' and contains detailed financial data for the quarter and half-year ended 31 December 2023, including revenue figures, cash balances, and operational highlights. It discusses product sales growth, partnerships, board changes, and clinical study updates. The length is substantial (15,000 characters), and it includes comprehensive financial and operational commentary, not just an announcement or summary. This matches the definition of an Interim / Quarterly Report (IR), which must contain actual financial statements or substantive financial data and analysis for a period shorter than a full fiscal year. Therefore, the document is classified as an Interim / Quarterly Report (IR).
2024-01-28 English
Notification regarding unquoted securities - OCC 9 pages 33.6KB
Share Issue/Capital Change Classification · 100% confidence The document is a detailed notification regarding the issue of unquoted equity securities, specifically options issued as part of the terms and conditions of a director appointment. It includes specifics such as the number of securities, issue dates, exercise prices, and references to ASX listing rules. The content focuses on the issuance of new securities rather than financial results, management changes, or regulatory compliance filings. It is not a full financial report, earnings release, or management discussion. The document fits the category of announcements related to new share issues or capital changes, which corresponds to the 'Share Issue/Capital Change' category (SHA). The document length and detail confirm it is not a brief announcement or a report publication notice, but a substantive notification of capital change.
2024-01-16 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.